TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9059105

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.25% in Entonox
Number of subjects: 35

Group type: COMPARATOR
Intervention: Entonox
Number of subjects: 35
Study: 8404107

Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 to 25 micrograms/kg/min)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Norepinephrine (0.5 to 5.0 micrograms/kg/min)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Norepinephrine added after dopamine failure
Number of subjects: 32
Study: 3777548

Group type: EXPERIMENTAL
Intervention: Moderate normovolaemic haemodilution induced with a colloid solution (Plasmion)
Number of subjects: 40
Study: 31461801

Group type: EXPERIMENTAL
Intervention: 5 μg dexmedetomidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 50 mg MgSO4
Number of subjects: 90

Group type: COMPARATOR
Intervention: NaCl 0.9% (Control)
Number of subjects: 90
Study: 29119631

Group type: EXPERIMENTAL
Intervention: Early start deferiprone (ES-DFP) at a low dose (50 mg/kg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Delay chelation (DC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Early start deferiprone (ES-DFP)
Number of subjects: 64
Study: 27819429

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) regarding student drinking and other college parents' alcohol-related communication
Number of subjects: 399

Group type: COMPARATOR
Intervention: General college health norm information
Number of subjects: 399
Study: 25266049

Group type: EXPERIMENTAL
Intervention: BMI <18.5
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: BMI 18.5 - 25
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: BMI 25 - 29
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: BMI ≥30
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Increasing BMI
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: CA 19-9 levels
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: ECOG < 2
Number of subjects: 483
Study: 22981555

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily for 6 weeks
Number of subjects: 21
Study: 20353120

Group type: EXPERIMENTAL
Intervention: Acupoint injection at Neiguan (PC 6) with 2.5 mg Droperidol (1 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous injection with 1 mL Droperidol
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study: 18718815

Group type: COMPARATOR
Intervention: Endocrine therapy alone (goserelin and anastrozole or goserelin and tamoxifen)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Anastrozole (without zoledronic acid)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid (goserelin, anastrozole, and zoledronic acid or goserelin, tamoxifen, and zoledronic acid)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Endocrine therapy alone (without zoledronic acid)
Number of subjects: 404
Study: 15981721

Group type: EXPERIMENTAL
Intervention: FLASH‐3D sequence with center of k-space acquisition after 8.7 s
Number of subjects: 20

Group type: COMPARATOR
Intervention: FLASH‐3D sequence with center of k-space acquisition after 0.5 s
Number of subjects: 20
Study: 12860219

Group type: EXPERIMENTAL
Intervention: berberine 1.2 to 2.0 g/day
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: berberine
Number of subjects: 156

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 156
Study: 11028252

Group type: EXPERIMENTAL
Intervention: Intravenous RGD891
Number of subjects: 0
Study: 8622227

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 39
Study: 1815231

Group type: EXPERIMENTAL
Intervention: Hydrogel dressings
Number of subjects: 107

Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 107
Study: 6360400

Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg single oral dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (2 tablets, each containing 500 mg of sulfadoxine plus 25 mg of pyrimethamine)
Number of subjects: 20
Study: 31038979

Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich PRP (LR-PRP)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor PRP (LP-PRP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 57
Study: 30152291

Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26398741

Group type: EXPERIMENTAL
Intervention: 2 doses of MenACWY-CRM (ACWY2)
Number of subjects: 715

Group type: COMPARATOR
Intervention: 1 dose of placebo followed by 1 dose of MenACWY-CRM (ACWY1)
Number of subjects: 715
Study: 24876616

Group type: EXPERIMENTAL
Intervention: Simultaneous pump and CGM initiation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard pump therapy with delayed CGM initiation
Number of subjects: 20
Study: 22252825

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg once daily (QD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg once daily (QD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (BID)
Number of subjects: 19
Study: 18971247

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 0.72 mg/24 h
Number of subjects: 154

Group type: COMPARATOR
Intervention: Glyceryl trinitrate 1.44 mg/24 h
Number of subjects: 154

Group type: COMPARATOR
Intervention: Glyceryl trinitrate 3.6 mg/24 h
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo patch application
Number of subjects: 154
Study: 17497969

Group type: EXPERIMENTAL
Intervention: Clamped drain group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous suction drainage group
Number of subjects: 66
Study: 15905658

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 75
Study: 12498842

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.2 mg/mL), applied topically with a soaked microsponge for 2 minutes after PRK
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no treatment with mitomycin-C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (0.2 mg/mL)
Number of subjects: 60
Study: 9620109

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril and Moexipril
Number of subjects: 0
Study: 8208874

Group type: EXPERIMENTAL
Intervention: Lithium plus early morning sleep deprivation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lithium plus control sleep deprivation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Desipramine with early morning sleep deprivation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Desipramine with control sleep deprivation
Number of subjects: 16
Study: 2645415

Group type: EXPERIMENTAL
Intervention: Diphenhydramine + DEC
Number of subjects: 107

Group type: COMPARATOR
Intervention: DEC alone
Number of subjects: 107
Study: 30558984

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with oral ciprofloxacin (2 doses prior to urinary catheter removal)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no antibiotics prior to urinary catheter removal)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with oral ciprofloxacin
Number of subjects: 167
Study: 28499433

Group type: EXPERIMENTAL
Intervention: ServAR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verbal information on standard serving sizes
Number of subjects: 90

Group type: COMPARATOR
Intervention: No information/aid (control)
Number of subjects: 90
Study: 25183287

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg kg(‐1) h(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg kg(‐1) h(‐1))
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 45
Study: 22405257

Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics (ICM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Topical mydriatics (TM)
Number of subjects: 60
Study: 21425144

Group type: EXPERIMENTAL
Intervention: Immediate treatment with loop electrical excision procedure (LEEP)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Colposcopic follow-up for 18 months
Number of subjects: 415
Study: 20394132

Group type: EXPERIMENTAL
Intervention: Online video assignment (experimental group, n = 42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No online video assignment (control group, n = 42)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 84
Study: 17310835

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy by antiandrogens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antineoplastic chemotherapeutic agents such as estramustine and taxanes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies including systemic therapy before or after local treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of rapamycin and its analogs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapeutic approach strategies
Number of subjects: 0
Study: 15557515

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 11984381

Group type: EXPERIMENTAL
Intervention: Home nursing care interventions
Number of subjects: 148
Study: 9672930

Group type: EXPERIMENTAL
Intervention: Intramuscular tenoxicam 0.75 mg.kg‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate 0.2 mg.kg‐1
Number of subjects: 50
Study: 7513776

Group type: EXPERIMENTAL
Intervention: Aprotinin (30,000 U/kg after induction of anesthesia, 30,000 U/kg added to the prime of the cardiopulmonary bypass)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without aprotinin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aprotinin and Control
Number of subjects: 30
Study: 2661444

Group type: EXPERIMENTAL
Intervention: Parenzan‐Fumero pump
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional roller pump
Number of subjects: 87
Study: 1215545

Group type: EXPERIMENTAL
Intervention: 15 (S) 15 methyl prostaglandin F2alpha injected intra-amniotically
Number of subjects: 0

Group type: COMPARATOR
Intervention: PGF2Alpha (comparison group)
Number of subjects: 0
Study: 31807987

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP), 5 sessions weekly, 10-20 min/session
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional physical rehabilitation (CON)
Number of subjects: 31
Study: 30686636

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg for 28 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of atorvastatin vs placebo
Number of subjects: 22
Study: 27080326

Group type: EXPERIMENTAL
Intervention: Drug therapy (DT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Bladder training (BT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combined pelvic floor rehabilitation (CPFR)
Number of subjects: 164
Study: 26498129

Group type: EXPERIMENTAL
Intervention: High-salt diet (∼14 g day(‐1) NaCl)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, non-selective COX-1 and COX-2 inhibitor)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg, selective COX-2 inhibitor)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-salt diet (<2.3 g day(‐1) NaCl)
Number of subjects: 54
Study: 23909286

Group type: EXPERIMENTAL
Intervention: Maternal homeostasis model assessment of insulin resistance at the 32nd week of gestation
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Change in serum triglycerides during pregnancy
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cord plasma insulin
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Stratification by gender
Number of subjects: 208
Study: 21752462

Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counselling (one antenatal visit and four post-delivery visits)
Number of subjects: 2579

Group type: COMPARATOR
Intervention: Control (no peer counselling)
Number of subjects: 2579

Group type: EXPERIMENTAL
Intervention: Breastfeeding peer counselling
Number of subjects: 2579
Study: 19188575

Group type: EXPERIMENTAL
Intervention: XP13512 1,200 mg once daily
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 17101479

Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine/Zinc Pyrithione shampoo (1.5% CPO/1% ZP)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Ketoconazole gel (2%)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Vehicle shampoo
Number of subjects: 189
Study: 15553106

Group type: EXPERIMENTAL
Intervention: emedastine 4 mg o.d.
Number of subjects: 120

Group type: COMPARATOR
Intervention: cetirizine 10 mg o.d.
Number of subjects: 120
Study: 11708590

Group type: EXPERIMENTAL
Intervention: Imitation sessions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (playing with the child)
Number of subjects: 20
Study: 9179098

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7956403

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 625

Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 625
Study: 31443735

Group type: EXPERIMENTAL
Intervention: Intervention group (rehabilitation treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 27834492

Group type: EXPERIMENTAL
Intervention: Beetroot Crystals (BC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (Bi)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined Beetroot Crystals and Sodium Bicarbonate (BC+Bi)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 25638483

Group type: EXPERIMENTAL
Intervention: Bear Essentials parent training plus distraction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Distraction only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 23972452

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ajust
Number of subjects: 171
Study: 21324184

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel-based chemotherapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: 3-weekly docetaxel-based chemotherapy
Number of subjects: 139
Study: 18304128

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 7 micro/kg
Number of subjects: 23
Study: 17699253

Group type: EXPERIMENTAL
Intervention: Combination treatment (prednisolone, azathioprine, warfarin, and dipyridamole)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combination treatment and Prednisolone alone
Number of subjects: 80
Study: 12714472

Group type: EXPERIMENTAL
Intervention: Manual therapy (spinal mobilisation)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Physiotherapy (mainly exercise)
Number of subjects: 183

Group type: COMPARATOR
Intervention: General practitioner care (counselling, education, and drugs)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: General practitioner care
Number of subjects: 183
Study: 10917579

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent flow reserve
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resting forearm blood flow (FBF)
Number of subjects: 44
Study: 8923338

Group type: EXPERIMENTAL
Intervention: Cloninger Temperament and Character Inventory (TCI)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Millon Clinical Multiaxial Inventory (MCMI‐II)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cloninger's character dimensions (self-transcendence)
Number of subjects: 103
Study: 1572459

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg and dipyridamole 150 mg twice daily
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: No detectable serum concentration (less than 50 ng ml‐1)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Corrected for risk factors
Number of subjects: 145
Study: 3863219

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilastatin
Number of subjects: 0
Study: 30636626

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 29500675

Group type: EXPERIMENTAL
Intervention: Investigational multivitamin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard multivitamin
Number of subjects: 56
Study: 26856320

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg/kg/h continuous infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23683727

Group type: EXPERIMENTAL
Intervention: Unilateral DXA for women
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Unilateral DXA for men
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Contralateral femoral DXA for women
Number of subjects: 2964

Group type: EXPERIMENTAL
Intervention: Unilateral femoral DXA
Number of subjects: 2964
Study: 23107780

Group type: EXPERIMENTAL
Intervention: Curcumin 2 grams/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Curcumin 4 grams/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20305368

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 400 IU/day + calcium 500 mg/day (D/Cal group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo + calcium 500 mg/day (Plac/Cal group)
Number of subjects: 70
Study: 16919319

Group type: EXPERIMENTAL
Intervention: 20 mg D‐amphetamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Stress reactivity
Number of subjects: 44
Study: 16325037

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day (F group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (diet) (C group)
Number of subjects: 40
Study: 12065465

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9484961

Group type: EXPERIMENTAL
Intervention: Artemether (intramuscular injection)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Quinine (intravenous infusion)
Number of subjects: 164
Study: 7658952

Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isotonic preload knee extension resistance training
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Isokinetic training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 2692820

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 114
Study: 62992

Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral chloramphenicol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral chloramphenicol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral co‐trimoxazole
Number of subjects: 0
Study: 31520255

Group type: EXPERIMENTAL
Intervention: Proactive care (PC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 20
Study: 31081371

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1544

Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 1544
Study: 27842473

Group type: EXPERIMENTAL
Intervention: Virtual Hope Box (VHB)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (printed materials about coping with suicidality)
Number of subjects: 118
Study: 25885325

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine (0-1-2-month schedule)
Number of subjects: 0
Study: 24053420

Group type: EXPERIMENTAL
Intervention: Communication with significant adults about sexuality issues
Number of subjects: 6251

Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 6251
Study: 21836134

Group type: EXPERIMENTAL
Intervention: CPAP withdrawal (subtherapeutic CPAP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Continued CPAP (control)
Number of subjects: 41
Study: 19162029

Group type: EXPERIMENTAL
Intervention: Repeated intervention (performed by a registered nurse before discharge and repeated at 6-month intervals)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Initial intervention only (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Repeated intervention (after 6 months)
Number of subjects: 120
Study: 17284262

Group type: EXPERIMENTAL
Intervention: CT-fluoroscopy guidance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no CT-fluoroscopy guidance)
Number of subjects: 50
Study: 12871363

Group type: EXPERIMENTAL
Intervention: Dalteparin for 5 weeks after HRS
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo with venographically proven DVT
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Dalteparin and DVT risk
Number of subjects: 218
Study: 10865409

Group type: EXPERIMENTAL
Intervention: beta thal/HbE postsplenec
Number of subjects: 28